Thorne D, Hollings M, Seymour A, Adamson J, Dalrymple A, Ballantyne M, Gaca M
British American Tobacco, R&D, Southampton, Hampshire, SO15 8TL, UK.
Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire HG3 1PY, UK.
Mutat Res Genet Toxicol Environ Mutagen. 2018 Apr;828:46-54. doi: 10.1016/j.mrgentox.2018.01.008. Epub 2018 Feb 19.
There is a growing consensus that e-cigarettes hold the potential for reducing the harm associated with cigarette smoking. Recently published studies have reported in vitro testing of e-cigarettes, demonstrating reduced toxicological and biological effects. Few studies however have reported the use of e-cigarettes under extreme testing conditions. To assess the full mutagenic potential of a commercially available electronic-cigarette (Vype ePen), this study investigated the delivery of aerosol under extreme conditions, using a scaled-down 35 mm plate Ames bacterial reverse mutagenicity assay. S. typhimurium strains TA98, TA100, TA97, TA104 and E. coli WP2 uvrA pKM101 with or without metabolic activation (S9), were employed. Using a modified Vitrocell VC 10 exposure system 0, 180, 360, 540, 720 or 900 puffs of undiluted e-cigarette aerosol was generated and delivered to bacterial cultures aligned to reported human consumption data. The results demonstrate that no mutagenic activity was observed in any strain under any test condition even when exposed to 900 puffs of undiluted e-cigarette aerosols +/- S9. Positive control responses were observed in all strains +/- S9. Nicotine assessments demonstrated an increased and consistent aerosol delivery, with calculated maximum doses of ∼1 mg/mL delivery of nicotine. These data demonstrate the validity of this unique testing approach and adds further information to the growing weight of evidence that e-cigarettes offer substantially reduced exposure when compared to conventional cigarette smoke. For future in vitro assessments of next generation tobacco and nicotine products, the generation, delivery and testing of undiluted aerosols can now be considered.
越来越多的人达成共识，即电子烟有可能减少与吸烟相关的危害。最近发表的研究报告了电子烟的体外测试，证明其毒理学和生物学效应有所降低。然而，很少有研究报告在极端测试条件下使用电子烟的情况。为了评估一种市售电子烟（Vype ePen）的全部致突变潜力，本研究使用按比例缩小的35毫米平板艾姆斯细菌回复突变试验，在极端条件下研究了气溶胶的递送情况。使用了鼠伤寒沙门氏菌菌株TA98、TA100、TA97、TA104和大肠杆菌WP2 uvrA pKM101，有或没有代谢活化（S9）。使用改良的Vitrocell VC 10暴露系统，产生0、180、360、540、720或900口未稀释的电子烟气溶胶，并将其递送至与报告的人类消费数据一致的细菌培养物中。结果表明，即使在任何测试条件下暴露于900口未稀释的电子烟气溶胶±S9，任何菌株均未观察到致突变活性。在所有菌株±S9中均观察到阳性对照反应。尼古丁评估表明气溶胶递送增加且一致，计算得出的尼古丁最大递送剂量约为1mg/mL。这些数据证明了这种独特测试方法的有效性，并为越来越多的证据增添了进一步的信息，即与传统香烟烟雾相比，电子烟的暴露量大幅降低。对于未来下一代烟草和尼古丁产品的体外评估，现在可以考虑未稀释气溶胶的产生、递送和测试。
